BiotechTube

Insulin + insulin

ApprovedCompleted
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Diabete Type 2

Conditions

Diabete Type 2, Hyperglycemia

Trial Timeline

Jan 1, 2016 → Dec 31, 2019

NCT ID
NCT05752929

About Insulin + insulin

Insulin + insulin is a approved stage product being developed by Rafael Holdings for Diabete Type 2. The current trial status is completed. This product is registered under clinical trial identifier NCT05752929. Target conditions include Diabete Type 2, Hyperglycemia.

Hype Score Breakdown

Clinical
30
Activity
20
Company
2
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT05752929ApprovedCompleted

Competing Products

20 competing products in Diabete Type 2

See all competitors
ProductCompanyStageHype Score
add-on pioglitazone + add-on sulphonylureaAMD BiotechApproved
77
MKP10241 + PlaceboMankind PharmaPhase 2
52
Daily injection of KBP/placebo for up to 28 daysEli LillyPhase 1
33
LY3209590 + Insulin DegludecEli LillyPhase 1
33
AC2993Eli LillyPhase 3
77
LY3209590 + PlaceboEli LillyPhase 1
33
Insulin Lispro Protamine Suspension + Insulin GlargineEli LillyPhase 3
77
LY2963016 + LantusEli LillyPhase 1
33
Empagliflozin + Other SGLT2 inhibitors + Other non-insulin GLDsEli LillyPre-clinical
23
Insulin Lispro Mix25 + Insulin Lispro Mix50Eli LillyApproved
85
Nasal Glucagon + Intramuscular GlucagonEli LillyPhase 3
77
Retatrutide + PlaceboEli LillyPhase 1
33
AG019 - Low Dose + Teplizumab + Placebo-AG019 + Placebo-Teplizumab + AG019 - High Dose + AG019 - High DosePrecigenPhase 1/2
36
LY4057996 SC + LY4057996 IV + Placebo SC + Placebo IV + Degludec SC + Lispro SC + Degludec IV + Pre-study basal insulin SCEli LillyPhase 1
33
Placebo + LinagliptinEli LillyPhase 3
77
Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Eli LillyApproved
85
teplizumab or placeboEli LillyPhase 1
33
LY2428757 + PlaceboEli LillyPhase 2
52
Insulin Efsitora Alfa + Insulin DegludecEli LillyPhase 3
77
LY900014 (SC) + LY900014 (IV)Eli LillyPhase 1
33

Other Products from Rafael Holdings

Varenicline + Nicotine patchApproved
77
Polyethylene glycol 4000 + Macrogol 3350 plus ascorbic acidApproved
77
inhaled corticosteroid plus LABA plus oral corticosteroidApproved
77
IV trivalent saccharose hydroxide ferrous + Oral ferrous fumarate + Oral and intravenous PlaceboApproved
77
Tacrolimus with rapid steroid withdrawal + Tacrolimus with steroids minimization + CsA with steroid minimizationApproved
77